Promyelocytic leukemia protein induces apoptosis due to caspase-8 activation via the repression of NFκB activation in glioblastoma

Neuro-Oncology

Volumn 11, Issue 2, 2009, Pages 132-141

  Kuwayama, Kazuyuki ^a   Matsuzaki, Kazuhito ^a   Mizobuchi, Yoshihumi ^a   Mure, Hideo ^a   Kitazato, Keiko T ^a   Kageji, Teruyoshi ^a   Nakao, Mitsuyoshi ^b   Nagahiro, Shinji ^a  

^a UNIVERSITY OF TOKUSHIMA   (Japan)

^b KUMAMOTO UNIVERSITY   (Japan)

Author keywords

Apoptosis; Caspase; Glioblastoma; NF B p65; Promyelocytic leukemia

Indexed keywords

CASPASE 8; FLICE INHIBITORY PROTEIN; I KAPPA B ALPHA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MESSENGER RNA; PROMYELOCYTIC LEUKEMIA PROTEIN; SUPPRESSOR OF CYTOKINE SIGNALING; SYNAPTOTAGMIN I;

APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL DEATH; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME REGULATION; ENZYME REPRESSION; GLIOBLASTOMA; HUMAN; HUMAN CELL; HUMAN TISSUE; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION;

APOPTOSIS; BLOTTING, WESTERN; CASPASE 8; CELL LINE, TUMOR; ENZYME ACTIVATION; FEMALE; GLIOBLASTOMA; HUMANS; I-KAPPA B PROTEINS; IMMUNOENZYME TECHNIQUES; MALE; MIDDLE AGED; NF-KAPPA B; NUCLEAR PROTEINS; PHOSPHORYLATION; PROTEASOME ENDOPEPTIDASE COMPLEX; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TRANSCRIPTION FACTORS; TUMOR SUPPRESSOR PROTEINS;

EID: 65949102979     PISSN: 15228517     EISSN: 15235866     Source Type: Journal    
DOI: 10.1215/15228517-2008-083     Document Type: Article

References (40)

1. Burger PC, Vogel FS, Green SB, Strike TA. Glioblastoma multiforme and anaplastic astrocytoma. Pathologic criteria and prognostic impli- cations. Cancer. 1985;56:1106-1111.
2. Kim TS, Halliday AL, Hedley-Whyte ET, Convery K. Correlates of sur- vival and the Daumas-Duport grading system for astrocytomas. J Neurosurg. 1991;74:27-37.
3. Fine HA, Dear KB, Loeffler JS, Black PM, Canellos GP. Meta-analis of radiation therapy with and without adjuvant chemotherapy for malignant gliomas in adults. Cancer. 1993;71:2585-2597.
4. Murphy C, Pickles T, Knowling M, Thiesse B. Concurrent modified PCV chemotherapy and radiotherapy in newly diagnosed grade IV astrocytoma. J Neurooncol. 2002;57:215-220.
5. Aldape KD, Okcu MF, Bondy ML, Wrensch M. Molecular epidemiol- ogy of glioblastoma. Cancer J. 2003;9:99-106.
6. Ohgaki H. Genetic pathways to glioblastomas. Neuropathology. 2005;25:1-7.
7. de The H, Lavau C, Marchio A, et al. The PML-RAR alpha fusion mRNA generated by the t(15;17) translocation in acute promyelocytic leuke- mia encodes a functionally altered RAR. Cell. 1991;66:675-684.
8. Pandolfi PP. Oncogenes and tumor suppressors in the molecular pathogenesis of acute promyelocytic leukemia. Hum Mol Genet. 2001;10:769-775.
9. Zhong S, Salomoni P, Pandolfi PP. The transcriptional role of PML and the nuclear body. Nat Cell Biol. 2000;2:E85-E90.
10. Lin RJ, Sternsdorf T, Tini M, Evans RM. Transcriptional regulation in acute promyelocytic leukemia. Oncogene. 2001;20:7204-7215.
11. Yeager TR, Neumann AA, Englezou A, et al. Telomerase-negative immortalized human cells contain a novel type of promyelocytic leu- kemia (PML) body. Cancer Res. 1999;59:4175-4179.
12. Ferbeyre G, de Stanchina E, Querido E, et al. PML is induced by oncogenic ras and promotes premature senescence. Genes Dev. 2000;14:2015-2027.
13. Pearson M, Carbone R, Sebastiani C, et al. PML regulates p53 acety- lation and premature senescence induced by oncogenic Ras. Nature. 2000;406:207-210.
14. Zhong S, Hu P, Ye TZ, et al. A role for PML and the nuclear body in genomic stability. Oncogene. 1999;18:7941-7947.
15. Bischof O, Kim SH, Irving J, et al. Regulation and localization of the Bloom syndrome protein in response to DNA damage. J Cell Biol. 2001;153:367-380.
16. Lee HE, Jee CD, Kim MA, et al. Loss of promyelocytic leukemia protein in human gastric cancers. Cancer Lett. 2007;247:103-109.
17. Gambacorta M, Flenghi L, Fagioli M, et al. Heterogeneous nuclear expression of the promyelocytic leukemia (PML) protein in normal and neoplastic human tissues. Am J Pathol. 1996;149:2023-2035.
18. Koken MH, Linares-Cruz G, Quignon F, et al. The PML growth- suppressor has an altered expression in human oncogenesis. Onco- gene. 1995;10:1315-1324.
19. Gurrieri C, Capodieci P, Bernardi R, et al. Loss of the tumor suppressor PML in human cancers of multiple histologic origins. J Natl Cancer Inst. 2004;96:269-279.
20. Chan JY, Chin W, Liew CT, Chang KS, Johnson PJ. Altered expres- sion of the growth and transformation suppressor PML gene in human hepatocellular carcinomas and in hepatitis tissues. Eur J Cancer. 1998;34:1015-1022.
21. Cho Y, Lee I, Maul GG, Yu E. A novel nuclear substructure, ND10: distribution in normal and neoplastic human tissues. Int J Mol Med. 1998;1:717-724.
22. Wu WS, Xu ZX, Hittelman WN, et al. Promyelocytic leukemia protein sensitizes tumor necrosis factor alpha-induced apoptosis by inhibit- ing the NF-kappaB survival pathway. J Biol Chem. 2003;278:12294-12304.
23. Wu WS, Xu ZX, Chang KS. The promyelocytic leukemia protein represses A20-mediated transcription. J Biol Chem. 2002;277:31734-31739.
24. Matsuzaki K, Minami T, Tojo M et al. PML-nuclear bodies are involved in cellular serum response. Genes Cells. 2003;8:275-286.
25. Karin M. Nuclear factor-kappaB in cancer development and progres- sion. Nature. 2006;441:431-436.
26. Pahl HL. Activators and target genes of Rel/NF-kappaB transcription factors. Oncogene. 1999;18:6853-6866.
27. Irmler M, Thome M, Hahne M, et al. Inhibition of death receptor sig- nals by cellular FLIP. Nature. 1997;388:190-195.
28. Sakurai H, Chiba H, Miyoshi H, Sugita T, Toriumi W. IkappaB kinases phosphorylate NF-kappaB p65 subunit on serine 536 in the transacti- vation domain. J Biol Chem. 1999;274:30353-30356.
29. Ryo A, Suizu F, Yoshida Y, et al. Regulation of NF-kappaB signaling by Pin1-dependent prolyl isomerization and ubiquitin-mediated pro- teolysis of p65/RelA. Mol Cell. 2003;12:1413-1426.
30. Wang ZG, Ruggero D, Ronchetti S, et al. PML is essential for multiple apoptotic pathways. Nat Genet. 1998;20:266-272.
31. Wang ZG, Delva L, Gaboli M, et al. Role of PML in cell growth and the retinoic acid pathway. Science. 1998;279:1547-1551.
32. Li L, He D, He H, et al. Overexpression of PML induced apoptosis in bladder cancer cell by caspase dependent pathway. Cancer Lett. 2006;236:259-268.
33. Son SH, Yu E, Choi EK, Lee H, Choi J. Promyelocytic leukemia protein- induced growth suppression and cell death in liver cancer cells. Cancer Gene Ther. 2005;12:1-11.
34. Quignon F, De Bels F, Koken M, et al. PML induces a novel caspase- independent death process. Nat Genet. 1998;20:259-265.
35. Sizemore N, Lerner N, Dombrowski N, Sakurai H, Stark GR. Distinct roles of the Ikappa B kinase alpha and beta subunits in liberating nuclear factor kappa B (NF-kappa B) from Ikappa B and in phosphory- lating the p65 subunit of NF-kappa B. J Biol Chem. 2002;277:3863-3869.
36. Nagai S, Washiyama K, Kurimoto M, et al. Aberrant nuclear factor- kappaB activity and its participation in the growth of human malig- nant astrocytoma. J Neurosurg. 2002;96:909-917.
37. Beg AA, Sha WC, Bronson RT, et al. Embryonic lethality and liver degeneration in mice lacking the RelA component of NFB. Nature. 1995;376:167-170.
38. Nagai M, Kurimoto M, Washiyama K, et al. Inhibition of cellular pro- liferation and induction of apoptosis by curcumin in human malignant astrocytoma cell lines. J Neurooncol. 2005;74:105-111.
39. Robe PA, Bentires-Alj M, Bonif M, et al. In vitro and in vivo activity of the nuclear factor-kappaB inhibitor sulfasalazine in human glioblasto- mas. Clin Cancer Res. 2004;10:5595-5603.
40. Kile BT, Schulman BA, Alexander WS, et al. The SOCS box: a tale of destruction and degradation. Trends Biochem Sci. 2002;27:235-241.